Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study

This multicenter phase 1/2 trial investigated the combination of bendamustine, lenalidomide, and dexamethasone in repeating 4-week cycles as treatment for relapsed refractory multiple myeloma (MM). Phase 1 established maximum tolerated dose (MTD). Phase 2 assessed overall response rate at the MTD. S...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Lentzsch, Suzanne, O'Sullivan, Amy, Kennedy, Ryan C., Abbas, Mohammad, Dai, Lijun, Pregja, Silvana Lalo, Burt, Steve, Boyiadzis, Michael, Roodman, G. David, Mapara, Markus Y., Agha, Mounzer, Waas, John, Shuai, Yongli, Normolle, Daniel, Zonder, Jeffrey A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2012
Gaiak:
Clinical Trials and Observations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3392072/
https://ncbi.nlm.nih.gov/pubmed/22451423
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-12-395715
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak